Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EU invests 10.7 million Euro on EICOSANOX - a top-ranking project led from Karolinska Institutet

14.02.2005


A decision has now been taken on the grant that the EU’s Sixth Framework Programme is to provide for EICOSANOX, a major research project coordinated by Karolinska Institutet’s Professor Jesper Z. Haeggström. The project, which ranked highest in its category, is an Integrated Project (IP) and is to be allocated research funding of 10.7 million euro over the course of five years. A total of 15 research groups from six European nations will be merged into a very large multi-disciplinary consortium, including a team from Canada and two biotech companies. The research is focused on prostaglandins, leukotrienes and nitric oxide, all of which are central to widespread diseases like cardiovascular disorders, atherosclerosis, dementia and cancer.



Several components of the project have given the EU cause to rank this project high:

• Relevance - it concerns important disease groups that are responsible for the majority of all deaths in Europe.
• European expertise – there is already unique expertise in Europe equal to the best in the USA and Japan.


• It has clear commercial potential, something which is given priority in the EU’s Sixth Framework Programme.

The research examines the enzyme systems that govern the formation of certain signal substances in the body, particularly derivatives of arachidonic acid. These substances control the course of events during inflammation and fever as well as blood coagulation and cellular growth. They are therefore of significance to several major disease areas, such as cardiovascular diseases, dementia and cancer. If scientists learn how to control these signal substances, they may be able to find suitable therapies. The annual global sales of drugs in these therapeutic areas have been estimated to more than 100 million Euro.

“I’ve hand-picked every single group involved,” says Professor Jesper Z. Haeggström, who is leading the consortium from Karolinska Institutet. “All of them are at the forefront of their specialist research fields.”

The consortium brings together research groups from Sweden, Germany, Italy, United Kingdom, Ireland and Spain, with three different specialisations: COX, LOX and NOS, abbreviations that stand for three different enzyme systems and their products. The systems and their functions are intimately integrated in the body, and the objective of the project is for the groups to meet and pool their knowledge. One important goal is to identify new genes that are involved in the regulation of COX, LOX and NOS, and that can be used to develop new drugs.

Enzymes of the COX family regulate the formation of prostaglandins from arachidonic acid (a fatty acid). “We block this system every time we take a normal aspirin, and this is also where the controversial COX-2 inhibitors, VIOXX and Celebrex, have their effect,” continues Professor Haeggström.

The second enzyme type, LOX, is necessary for the formation of leukotrienes, which are also derived from arachidonic acid. Important drugs have been produced in this area too, in particular the anti-leukotrienes that are used in the treatment of asthma and allergic hay fever. The third specialisation involves NOS, the enzyme active in the synthesis of nitric oxide, the central role of which has become all the more noted recently. The system is affected, for instance, during nitroglycerine therapy for angina and on the treatment of impotence with the now infamous Viagra.

Apart from four groups at Karolinska Institutet, the network formed through the consortium includes the University of Frankfurt, which has research groups in all three areas. Cardiologists from Italy’s D’Annunzio University are also involved, along with British researchers from the renowned William Harvey Institute and Salvador Moncada, one of the world’s most eminent researchers in the field of nitric oxide. The Canadian group is specialised in animal models for studies of eicosanoids. Two biotech companies, the Swedish Biolipox AB and the Franco-Italian NicOx, are also taking part.

Research into prostaglandins and leukotrienes (also known as eicosanoids) has long been a flagship field of research in Sweden and one in which we have led the world. The substances were discovered at Karolinska Institutet, which earned Sune Bergström and Bengt Samuelsson, together with John R. Vane from England, the Nobel Prize in Physiology or Medicine in 1982.

“Karolinska Institutet has trained many of today’s leading Japanese and American researchers in eicosanoids,” says Professor Haeggström.

The consortium includes four groups from Sweden and Karolinska Institutet:

• Professor Haeggström’s team at the Department of Medical Biochemistry and Biophysics, specialising in preclinical basic research into eicosanoids and the COX and LOX enzyme systems.
• Jon Lundberg’s team at the Department of Physiology and Pharmacology, specialising in nitric oxides and their role in the body’s immune systems.
• Göran K. Hansson’s team at the Department of Medicine at Karolinska University Hospital in Solna, specialising in clinical research into atherosclerosis and vascular inflammation.
• Pär Nordlund’s team, which has recently moved to Karolinska Institutet and the Department of Medical Biochemistry and Biophysics in order to work with determination of protein structures by X-ray crystallography at large scale.

“For us at Karolinska Institutet, this grant provides valuable long-term basic support at a time when national medical research funds have been completely drained,” says Professor Haeggström. “Each one of the four KI groups will receive between 50 000 and 200 000 Euro per year for five years, and we’ll also be getting extra resources for the administration and coordination of the consortium.”

Jesper Z. Haeggström | alfa
Further information:
http://www.mbb.ki.se

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>